WASHINGTON — Glucagon-like peptide-1 receptor agonists significantly reduced alanine aminotransferase levels in pediatric metabolic dysfunction-associated steatotic liver disease, especially those with type 2 diabetes, researchers reported.
“The study was prompted by my interest in the use of anti-obesity medications in the treatment of MASLD,” Jennifer A. Panganiban, MD,